摘要
目的:观察重组人白介素-11(rhIL-11)对恶性肿瘤患者因化疗所致血小板减少的疗效及毒副反应。方法:化疗后血小板低于25×109/L给予rhIL-11 50μg/(kg.d)皮下注射,血小板低于50×109/L给予rhIL-11 25μg/(kg.d)皮下注射,观察外周血小板变化,血小板升至≥75×109/L时停药。结果:血小板升至≥75×109/L所需时间:Ⅲ度22例(5.0±1.3)天,Ⅳ度8例(12.4±1.6)天。主要毒副反应为乏力、水肿、关节肌肉疼痛、注射部位疼痛。结论:重组人白介素-11(rhIL-11)有升高化疗后血小板减少的作用,毒副反应可耐受。
Objective ：To observe the efficacy and side effects of recombinant human interleukin-11 （rhIL-11 ）in the treatment of thrombocytopenia caused by chemotherapy in patients with malignancies. Methods：Platelets after chemotherapy less than 30 × 10^9/L were injected subcutaneously with rhIL-11 501xg/（ kg.d）, platelets less than 50 × 10^9/L with rhIL-11 25μg/（kg·d） subcutaneous injection to observe changes in peripheral platelet until the counts of platelets came to 75 × 10^9/L. Results：Observed the time required to platelets increased to ≥75 × 10^9/L. The time to grade Ⅲ thrombocytopenia were（5.0 ± 1.3 ） days,and that of grade Ⅳ were（ 12.4 ±1.6） days. The main side effects including fatigue, edema,local pain of injection, arthralgia/muscular soreness. Conclusion： Recombinant human interleukin-11 （ rhIL-11 ） can elevate blood platelet count and a effective drug for treatment of thrombocytopenia caused by chemotherapy. Adverse reactions can be tolerated.
出处
《临床肿瘤学杂志》
CAS
2009年第5期452-453,共2页
Chinese Clinical Oncology
关键词
重组人白介素-11
化学治疗
血小板减少
Recombinant human interleukin-11 （ rhIL-11 ）
Chemotherapy
Thrombocytopenia
